Anthony H. Cincotta - Concepedia

Author

Anthony H. Cincotta

Also Known As

, A H Cincotta, A. Cincotta, A. H. Cincotta, A.H. Cincotta, ANTHONY CINCOTTA, ANTHONY H. CINCOTTA, Anthony Cincotta, Anthony H Cincotta, Anthony H. Cincotta

105

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Veroscience (United States)Harvard University Energy Research Company (United States)Louisiana State University Massachusetts General Hospital

About

Anthony H. Cincotta is an author at Veroscience (United States) specializing in medicine, pharmacology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	26	1.2K
2	Health Sciences	14	18	826
3	Biochemistry	9	9	435
4	Cell Biology	3	3	76
5	Allergy	1	1	12

Anthony H. Cincotta

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Bromocriptine: a novel approach to the treatment of type 2 diabetes. Hanno Pijl, Satoru Ohashi, Masafumi Matsuda, Diabetes Care	2000	239
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes J. Michael Gaziano, Anthony H. Cincotta, Christopher M. O’Connor, Diabetes Care	2010	210
Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob Mice Keshavan G. Bina, Anthony H. Cincotta Neuroendocrinology	2000	150
Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes Anthony H. Cincotta, Albert Meier, M. Cincotta Expert Opinion on Investigational Drugs ObesityMetabolic SyndromeDiabetes ManagementMedicineInsulin Management	1999	138
Bromocriptine (Ergoset) Reduces Body Weight and Improves Glucose Tolerance in Obese Subjects Anthony H. Cincotta, Albert Meier Diabetes Care	1996	134
Effects of a Quick-Release Form of Bromocriptine (Ergoset) on Fasting and Postprandial Plasma Glucose, Insulin, Lipid, and Lipoprotein Concentrations in Obese Nondiabetic Hyperinsulinemic Women Vinaya Kamath, C. N. O. Jones, Jeannie C Yip, Diabetes Care	1997	104
Bromocriptine Reduces Obesity, Glucose Intolerance and Extracellular Monoamine Metabolite Levels in the Ventromedial Hypothalamus of Syrian Hamsters Shuqin Luo, Albert Meier, Anthony H. Cincotta Neuroendocrinology	1998	98
Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes Richard E. Scranton, Anthony H. Cincotta Expert Opinion on Pharmacotherapy	2009	95
Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects J. Michael Gaziano, Anthony H. Cincotta, Aaron I. Vinik, Journal of the American Heart Association	2012	92
Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice Anthony H. Cincotta, Effie Tozzo, Piotr W.D. Ścisłowski Life Sciences ObesityMetabolic SyndromeEnergy HomeostasisMetabolic DysfunctionsMedicine	1997	90

Page 1